http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 31 Jul 2026 08:11:51 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Bicycle+Therapeutics+%28BCYC%29+PT+Lowered+to+%2411+at+Oppenheimer/26847069.html Oppenheimer analyst Jay Olson lowered the price target on Bicycle Therapeutics (NASDAQ: BCYC) to $11.00 (from $36.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Bicycle+Therapeutics+%28BCYC%29+PT+Lowered+to+%2411+at+Oppenheimer/26847069.html Fri, 31 Jul 2026 08:11:51 -0400 BCYC http://www.streetinsider.com/Earnings/Bicycle+Therapeutics+plc+%28BCYC%29+Misses+Q2+EPS+by+15c/26839032.html <p>Bicycle Therapeutics plc (NASDAQ: BCYC) reported Q2 EPS of ($0.72), $0.15 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $630 thousand versus the consensus estimate of $4.35 million.</p><p>For earnings history and earnings-related data on Bicycle Therapeutics plc (BCYC) <a href="http://www.streetinsider.com/ec_earnings.php?q=BCYC">click here</a>.</p> http://www.streetinsider.com/Earnings/Bicycle+Therapeutics+plc+%28BCYC%29+Misses+Q2+EPS+by+15c/26839032.html Thu, 30 Jul 2026 07:52:00 -0400 BCYC http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Press+Releases/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html <p class="bwalignc"> <i>Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities</i> </p><p class="bwalignc"> <i>Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D.</i> </p><p class="bwalignc"> <i>Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030</i> </p> <p> CAMBRIDGE, England &amp; BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June http://www.streetinsider.com/Business+Wire/Bicycle+Therapeutics+Reports+Recent+Business+Progress+and+Second+Quarter+2026+Financial+Results/26838355.html Thu, 30 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 A.35552990 A.50216726 BCYC O.00074346 O.20026344 O.21612337 O.22422661 O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Skynner+Michael/26784496.html si-local-file:///var/storage/secattach/20260717/26784496.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Skynner+Michael/26784496.html Fri, 17 Jul 2026 16:15:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Skynner+Michael/26784496.html si-local-file:///var/storage/secattach/20260717/26784496.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Skynner+Michael/26784496.html Fri, 17 Jul 2026 16:15:00 -0400 BCYC O.36852577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Perry+Jennifer+Scott/26784497.html si-local-file:///var/storage/secattach/20260717/26784497.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BICYCLE+THERAPEUTICS++++++For%3A+Jul+15++Filed+by%3A+Perry+Jennifer+Scott/26784497.html Fri, 17 Jul 2026 16:15:00 -0400 BCYC O.36852577